MAPT and Alzheimer disease: As anticipated, the significant reduction in the expression of these proteins in the brains of ABG-001-treated AD mice, as illustrated in Figure 7, strongly supports our conclusion that IPA, the main metabolite of ABG-001, is involved in CMA and contributes to the clearance of Aβ and the phosphorylation of Tau in the hippocampus and cerebral cortex of AD mice.